Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
09 mai 2024 07h00 HE
|
Amicus Therapeutics, Inc.
1Q 2024 Total Revenue of $110.4M, a 28% Increase Year-over-Year Guiding to Full-Year 2024 Total Revenue Growth of 25%-30% at CER Raising Full-Year 2024 Galafold® Guidance on Continued Strong Demand ...
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
08 mai 2024 07h00 HE
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2024 Health Care...
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
01 mai 2024 07h00 HE
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 9, 2024, at...
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
20 mars 2024 07h00 HE
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for...
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
01 mars 2024 07h00 HE
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor...
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
28 févr. 2024 07h00 HE
|
Amicus Therapeutics, Inc.
2023 Total Revenue of $399.4M, a 21% Increase Year-over-Year Strong Patient Demand Continues for Pombiliti™ + Opfolda™ in the U.S., U.K., and Germany Projecting 2024 Galafold® Revenue Growth of...
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
15 févr. 2024 07h00 HE
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 28,...
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
08 févr. 2024 07h00 HE
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that WORLDSymposium™ has awarded Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat)...
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
01 févr. 2024 07h00 HE
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and 11 posters across its development programs will be included at...
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
07 janv. 2024 16h00 HE
|
Amicus Therapeutics, Inc.
2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year >2,400 People Living with Fabry Disease on Galafold® Following a Year of Increased Demand Expecting 2024 Galafold Revenue Growth of...